iShares Short-Term California Muni Active ETF CALI 深 滬
交易中 10-10 11:24:56 美东时间
50.58
+0.030
+0.06%
華盛通- 最 高50.61
- 今 開50.59
- 成交量 1217股
- 最 低 50.58
- 昨 收 50.55
- 總市值 1.11亿
- 52周最高 50.6643
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 48.8974
- 委 比 -33.33%
- 總股本 220.00万
- 歷史最高 50.6643
- 量 比 0.23
- 振 幅 0.06%
- 歷史最低 -3.0657
- 每 手 1
- 風險率 0.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ClearPoint Neuro Secures Regulatory Approvals In Canada, Hong Kong, And Taiwan, Expanding Clinical Access To 34 Countries
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization.SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October
10-07 04:13
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics' CEO, Eric Poma, will participate in the Oncology Venture, Innovation, and Partnering Summit to discuss the company's RedTail platform, designed to deliver genetic medicines to metastatic sites. The platform aims to protect viruses from immune clearance and enhance tumor targeting. The company's lead candidate is in IND-enabling studies for cancers like non-small cell lung and ovarian cancer. The event, held in Boston, incl...
09-29 12:00
迈威生物的回购“迷局”
本文来自：锦缎研究院，作者：黄希文 前有“预告式”BD，现有“诱饵式”回购，部分创新药公司为了吸引投资者也是拼了。 自6月27日披露回购方案后，迈威生物至今回购...
09-12 09:20
CASI Pharmaceuticals Advances Anti-CD38 Antibody CID-103 To Next Dose Cohort In Phase 1 ITP Trial
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports continued development- No serious adverse events or dose-limiting
09-08 21:14
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions
BOSTON, Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING H...
08-30 04:05
Ainos Launches Patented AI Nose Platform For Industrial And Healthcare Markets, Unveils SmellTech-As-A-Service At Automation Taipei 2025
Patented AI Olfaction Platform Targets Semiconductor, Smart Factory, and Hospital Markets With First Deployments UnderwaySmellTech-as-a-Service Subscription Delivers AI Upgrades and Analytics, Keeping Enterprises Ahead
08-14 21:39
Caliber Sets Date for Second Quarter 2025 Earnings Announcement & Investor Conference Call
Caliber announced it will release its Q2 2025 financial results on August 13 after market close, with a webcast/conference call at 5:00 pm ET the same day. Investors can join via phone or the company’s website. Caliber, with $2.9 billion in managed assets, focuses on hospitality, multi-family, and industrial real estate, targeting overlooked opportunities.
07-31 03:13
GrabAGun.com Posts On X "BREAKING: AMMO NOW SHIPPING TO CALIFORNIA. The 9th Circuit has ruled California's ammunition restrictions unconstitutional—and we're proud to announce that GrabAGun is now shipping ammo directly to California customers. California is home to one of the largest communities of law-abiding gun owners in the country. This is a major win for the Second Amendment and for freedom-loving Americans across the state. Freedom is back on your doorstep."
https://x.com/grabagun/status/1948770295357038784
07-25 23:54
Renovaro Biosciences Announces Publication Of Peer-Reviewed Study In Vaccines; Says Preclinical Data Validate Renovaro's Platform Representing Step Forward In Fight Against Pancreatic And Solid Tumors
Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumorsLOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences
07-17 21:20
Novartis Gets Swiss Approval For First Malaria Drug For Babies
Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.
07-08 19:57
